{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_011",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:d41cc7bd937b16c7520e2ac52bef4ea5f2e5def82aeea32bc289438657d23598",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:34.526752",
  "content": "## 2024-05-13 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 105\n- Active: 101\n- Screen Failures Cumulative: 19\n- Withdrawals Cumulative: 4\n\n### Enrollment by Dose Group\n- Low Dose: 25\n- Mid Dose: 26\n- High Dose: 27\n- Placebo: 27\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 74.5\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 16.8\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 108.0\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 180.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 131.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 32.4\n- Mid Dose\n  - IgG Titer (GMU) Mean: 115.0\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 27.9\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 185.7\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 283.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 192.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 48.9\n- High Dose\n  - IgG Titer (GMU) Mean: 162.4\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 38.4\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 250.2\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 392.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 263.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 60.6\n- Placebo\n  - IgG Titer (GMU) Mean: 10.1\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 2.9\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 29.8\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 35.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 31.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 8.4\n\n### Injection Site Reactions\n- Pain Percentage: 43.4\n- Erythema Percentage: 21.1\n- Swelling Percentage: 5.5\n- Induration Percentage: 7.2\n- Mean Pain Duration (Hours): 27.6\n\n### Systemic Reactogenicity\n- Fever Percentage: 22.3\n- Fatigue Percentage: 32.0\n- Myalgia Percentage: 23.1\n- Headache Percentage: 23.9\n- Chills Percentage: 8.7\n\n### Safety Labs\n- WBC (K) Mean: 8.7\n- WBC (K) SD: 1.4\n- Lymphocyte Percentage Mean: 34.2\n- Lymphocyte Percentage SD: 7.6\n- Neutrophil Percentage Mean: 63.8\n- Neutrophil Percentage SD: 8.3\n- Platelets (K) Mean: 245\n- Platelets (K) SD: 42\n- CRP (mg/L) Mean: 3.6\n- CRP (mg/L) SD: 0.6\n- Hemoglobin (g/dL) Mean: 13.1\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-1137, Description: injection site pain, Grade: 1, Relatedness: related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1163, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1182, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Site 04 monitoring visit, 0 minor findings\n- DSMB safety review teleconference completed\n- Vaccination day 6: 22 subjects received scheduled dose\n\n### Notes\n- Week 11: Immunogenicity assessments on schedule. 105 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 11,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}